Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2105067 |
| _version_ | 1827806432801587200 |
|---|---|
| author | Suzanne M. Garland Manjula Anagani Neerja Bhatla Sukanta Chatterjee Sanjay Lalwani Cecil Ross Thomas Group Jianxin Lin Alain Luxembourg Anuj Walia Yingmei Tu |
| author_facet | Suzanne M. Garland Manjula Anagani Neerja Bhatla Sukanta Chatterjee Sanjay Lalwani Cecil Ross Thomas Group Jianxin Lin Alain Luxembourg Anuj Walia Yingmei Tu |
| author_sort | Suzanne M. Garland |
| collection | DOAJ |
| description | The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V501–029 [NCT00380367]) in Indian girls (aged 9–15 years; N = 110) evaluating qHPV vaccine immunogenicity and safety; a subgroup analysis (n = 225) of Indian girls/boys (9–15 years) and women (16–26 years) from a global study (V503–002 [NCT00943722]) evaluating 9vHPV vaccine immunogenicity and safety; and a qHPV vaccine post-marketing safety surveillance study (V501–125) in Indian females (aged 9–45 years; N = 188) vaccinated during routine care. In V501–029 and V503–002, HPV vaccines were administered as 3 doses (Day 1, Month 2, Month 6). Serum HPV antibodies were evaluated by competitive Luminex immunoassays at Day 1 and Month 7 (both studies) and Months 12, 24, and 36 (V503–002 only). Adverse events (AEs) were collected by Vaccination Report Card. In V501–125, participants were actively surveilled for serious AEs (SAEs) within 30 days post-qHPV vaccination. In per-protocol analyses, qHPV and 9vHPV vaccines induced robust anti-HPV6/11/16/18 (V501–029) and HPV6/11/16/18/31/33/45/52/58 (V503–002) responses, respectively; ≥97% of participants seroconverted at Month 7 for each vaccine HPV type in both studies, and antibody responses persisted through 36 months in V503–002. The most common AEs were injection-site-associated. Most AEs were mild/moderate; no deaths, vaccine-related SAEs, or discontinuations due to AEs were reported. In V501–125, no SAE was reported. Overall, the qHPV and 9vHPV vaccines elicited robust antibody responses and were generally well tolerated in Indian participants. |
| first_indexed | 2024-03-11T21:41:03Z |
| format | Article |
| id | doaj.art-cf2d2916be8d4ca599a28268dd9021ac |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:03Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-cf2d2916be8d4ca599a28268dd9021ac2023-09-26T13:19:08ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.21050672105067Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participantsSuzanne M. Garland0Manjula Anagani1Neerja Bhatla2Sukanta Chatterjee3Sanjay Lalwani4Cecil Ross5Thomas Group6Jianxin Lin7Alain Luxembourg8Anuj Walia9Yingmei Tu10The University of MelbourneCARE Super Specialty Hospital & Transplant CentreAll India Institute of Medical SciencesKPC Medical College & HospitalLalwani Mother & Child Care HospitalSt. John’s Medical College HospitalMerck & Co., IncMerck & Co., IncMerck & Co., IncMerck & Co., IncMerck & Co., IncThe quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V501–029 [NCT00380367]) in Indian girls (aged 9–15 years; N = 110) evaluating qHPV vaccine immunogenicity and safety; a subgroup analysis (n = 225) of Indian girls/boys (9–15 years) and women (16–26 years) from a global study (V503–002 [NCT00943722]) evaluating 9vHPV vaccine immunogenicity and safety; and a qHPV vaccine post-marketing safety surveillance study (V501–125) in Indian females (aged 9–45 years; N = 188) vaccinated during routine care. In V501–029 and V503–002, HPV vaccines were administered as 3 doses (Day 1, Month 2, Month 6). Serum HPV antibodies were evaluated by competitive Luminex immunoassays at Day 1 and Month 7 (both studies) and Months 12, 24, and 36 (V503–002 only). Adverse events (AEs) were collected by Vaccination Report Card. In V501–125, participants were actively surveilled for serious AEs (SAEs) within 30 days post-qHPV vaccination. In per-protocol analyses, qHPV and 9vHPV vaccines induced robust anti-HPV6/11/16/18 (V501–029) and HPV6/11/16/18/31/33/45/52/58 (V503–002) responses, respectively; ≥97% of participants seroconverted at Month 7 for each vaccine HPV type in both studies, and antibody responses persisted through 36 months in V503–002. The most common AEs were injection-site-associated. Most AEs were mild/moderate; no deaths, vaccine-related SAEs, or discontinuations due to AEs were reported. In V501–125, no SAE was reported. Overall, the qHPV and 9vHPV vaccines elicited robust antibody responses and were generally well tolerated in Indian participants.http://dx.doi.org/10.1080/21645515.2022.2105067clinical trialhuman papillomavirus vaccineimmunogenicityindiasafety |
| spellingShingle | Suzanne M. Garland Manjula Anagani Neerja Bhatla Sukanta Chatterjee Sanjay Lalwani Cecil Ross Thomas Group Jianxin Lin Alain Luxembourg Anuj Walia Yingmei Tu Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants Human Vaccines & Immunotherapeutics clinical trial human papillomavirus vaccine immunogenicity india safety |
| title | Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants |
| title_full | Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants |
| title_fullStr | Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants |
| title_full_unstemmed | Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants |
| title_short | Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants |
| title_sort | immunogenicity and safety of quadrivalent and 9 valent human papillomavirus vaccines in indian clinical trial participants |
| topic | clinical trial human papillomavirus vaccine immunogenicity india safety |
| url | http://dx.doi.org/10.1080/21645515.2022.2105067 |
| work_keys_str_mv | AT suzannemgarland immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT manjulaanagani immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT neerjabhatla immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT sukantachatterjee immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT sanjaylalwani immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT cecilross immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT thomasgroup immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT jianxinlin immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT alainluxembourg immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT anujwalia immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants AT yingmeitu immunogenicityandsafetyofquadrivalentand9valenthumanpapillomavirusvaccinesinindianclinicaltrialparticipants |